10-Q: Harrow Inc. Reports Increased Revenue but Net Loss in Second Quarter 2024

Harrow Inc. saw a significant increase in product sales but reported a net loss for the second quarter of 2024, according to its latest financial report.

Summary

• Harrow Inc. reported a net loss of $6.473 million for the three months ended June 30, 2024, and a net loss of $20.038 million for the six months ended June 30, 2024.
• Product sales increased to $48.871 million for the three months ended June 30, 2024, and $83.379 million for the six months ended June 30, 2024, compared to $29.542 million and $49.995 million for the same periods in 2023, respectively.
• The company's gross profit was $36.4 million for the three months ended June 30, 2024, and $60.434 million for the six months ended June 30, 2024.
• Operating expenses totaled $34.87 million for the three months ended June 30, 2024, and $65.832 million for the six months ended June 30, 2024.
• The company sold its investment in Eton Pharmaceuticals in April 2024, resulting in a loss of $3.171 million.
• Harrow's cash and cash equivalents were $70.968 million as of June 30, 2024, compared to $74.085 million at the end of 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is strong revenue growth and positive developments like the TRIESENCE PPQ batch and the Apotex agreement, the significant net loss and increased operating expenses are concerning. The sentiment is neutral to slightly negative due to the financial losses.

Positives

• Harrow experienced significant growth in product sales, indicating strong market demand for its offerings.
• The improvement in gross profit margin suggests better cost management and pricing strategies.
• The successful manufacture of a PPQ batch of TRIESENCE is a positive step towards its re-launch.
• The Apotex agreement expands Harrow's market reach into Canada.
• The CMS clarification and MUE increase for IHEEZO should improve reimbursement and usage.

Negatives

• The company reported a net loss of $6.473 million for the three months ended June 30, 2024, and $20.038 million for the six months ended June 30, 2024.
• Operating expenses increased significantly, impacting overall profitability.
• The sale of the Eton Pharmaceuticals investment resulted in a loss of $3.171 million.
• Cash reserves decreased slightly from the end of 2023.

Risks

• The company is subject to regulatory standards that could impact its ability to sell certain products.
• The company's ability to re-launch TRIESENCE depends on the successful manufacture of additional PPQ batches.
• The company's future success depends on its ability to manage costs, increase revenues, and obtain reimbursement for its products.
• The company is involved in various legal proceedings, which could have a material adverse effect on its financial results.
• The company relies on three main suppliers for its active pharmaceutical ingredients, which could pose a supply chain risk.

Future Outlook

The company expects to produce a third PPQ batch of TRIESENCE before the end of the third quarter 2024 and believes TRIESENCE could be re-launched in the U.S. prior to the end of 2024 if the three PPQ batches are manufactured successfully. The company also expects to use its current cash position and funds generated from operations to pursue its business plan.

Management Comments

• The company believes it has built a tangible and intangible infrastructure that will allow it to scale revenues efficiently in the near and long-term.
• The company may consider the sale of certain assets including, but not limited to, part of, or all of, its investments in Surface Ophthalmics, Inc. (Surface) and Melt Pharmaceuticals, Inc. (Melt) and any of its consolidated subsidiaries.

Industry Context

The company operates in the competitive eyecare pharmaceutical market, facing competition from other pharmaceutical companies, outsourcing facilities, and pharmacies. The company's focus on branded ophthalmic products and its compounding business positions it to capitalize on the growing demand for specialized eyecare treatments.

Comparison to Industry Standards

• Harrow's revenue growth in product sales is a positive sign, indicating a strong market presence and demand for its products. However, the net loss highlights the challenges in achieving profitability, which is a common issue for companies in the pharmaceutical industry, especially those in the development and commercialization phase.
• Compared to other pharmaceutical companies, Harrow's gross margin of 72.35% for the six months ended June 30, 2024, is relatively strong, suggesting efficient cost management. However, the high operating expenses are a concern and need to be addressed to improve profitability.
• The successful manufacture of a PPQ batch of TRIESENCE is a significant milestone, as it indicates progress in the company's product development pipeline. This is comparable to other pharmaceutical companies that are focused on bringing new products to market.
• The company's strategic partnerships, such as the agreement with Apotex, are in line with industry trends of expanding market reach through collaborations. This is a common strategy for pharmaceutical companies to leverage their products in different markets.
• The company's focus on obtaining reimbursement for its products, as seen with the CMS clarification for IHEEZO, is crucial for its long-term success. This is a key factor for pharmaceutical companies to ensure market access and adoption of their products.

Legal Proceedings

• ImprimisRx, LLC, a subsidiary of the Company, is involved in a lawsuit against Ocular Science, Inc. and OSRX, Inc. for copyright infringement, trademark infringement, unfair competition and false advertising.
• The company is involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict.

Related Party Transactions

• The company owns 3,500,000 shares of common stock and 2,334,256 shares of preferred stock of Melt Pharmaceuticals, Inc. (Melt), representing approximately 46% of Melt's equity interests as of June 30, 2024.
• The company's Chief Executive Officer, Mark L. Baum, is a member of the Melt board of directors.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the decrease in cash reserves.
• Employees may be impacted by the company's efforts to manage costs and increase revenues.
• Customers may benefit from the company's expanded product portfolio and improved market access.
• Suppliers may be affected by the company's reliance on three main suppliers for its active pharmaceutical ingredients.
• Creditors may be impacted by the company's debt obligations and its ability to service its debt.

Next Steps

• The company expects to produce a third PPQ batch of TRIESENCE before the end of the third quarter 2024.
• The company will continue to pursue its business plan, which includes developing and commercializing drug candidates, compounded formulations and technologies, integrating and developing its operations, and pursuing potential future strategic transactions.

Key Dates

Keywords

ophthalmic pharmaceuticals, product sales, net loss, gross profit, VEVYE, TRIESENCE, IHEEZO, Apotex, ImprimisRx, pharmaceutical compounding